Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXP72F)

Drug Name

OTS964 Drug Info

Synonyms

(R)-9-(4-(1-(dimethylamino)propan-2-yl)phenyl)-8-hydroxy-6-methylthieno[2,3-c]quinolin-4(5H)-one; 1338545-07-5; SCHEMBL2548561; GTPL7813; CHEMBL3672369; MolPort-044-561-385; ZINC149881647; SB19795; NCGC00484799-01; 9-{4-[(2R)-1-(dimethylamino)propan-2-yl]phenyl}-8-hydroxy-6-methyl-4H,5H-thieno[2,3-c]quinolin-4-one

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 67448186
TTD Drug ID: DMXP72F

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting PDZ binding kinase (PBK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
HITOPK-032	DM7MUJ3	Nasopharyngeal carcinoma	2B6B	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
PDZ binding kinase (PBK)	TTMY6BZ	TOPK_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci. 2010 Feb;101(2):403-11.
2	TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med. 2014 Oct 22;6(259):259ra145.
3	PDZ binding kinase (PBK) is a theranostic target for nasopharyngeal carcinoma: driving tumor growth via ROS signaling and correlating with patient survival.Oncotarget. 2016 May 3;7(18):26604-16.